Supplemental material
OncoImmunology
Volume 3, 2014 - Issue 2
Related Research Data
Processing and presentation of tumor antigens and vaccination strategies.
Source:
Elsevier BV
An autologous oral DNA vaccine protects against murine melanoma
Source:
Proceedings of the National Academy of Sciences
Targeting cancer with small-molecular-weight kinase inhibitors.
Source:
Humana Press
Dasatinib in solid tumors.
Source:
Informa Healthcare
Current Status of Src Inhibitors in Solid Tumor Malignancies
Source:
Alphamed Press
In vivo effects of TKIs on immune cells
Source:
Wiley
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells.
Source:
American Association for Cancer Research (AACR)
The cooperative induction of hypoxia-inducible factor-1α and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis
Source:
The American Association of Immunologists
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.
Source:
Informa UK Limited
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
Source:
American Society of Hematology
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Source:
American Association for Cancer Research (AACR)
Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape
Source:
Informa UK Limited
Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.
Source:
Springer Science and Business Media LLC
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Source:
American Association for Cancer Research (AACR)
Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Source:
Springer Science and Business Media LLC
Dendritic cell vaccines: A review of recent developments and their potential pediatric application
Source:
Informa UK Limited
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Source:
Elsevier BV
Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Source:
American Society of Hematology
A phase 2 trial of dasatinib in advanced melanoma
Source:
Wiley
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Source:
American Association for Cancer Research (AACR)
Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source:
Informa UK Limited
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Source:
Ovid Technologies (Wolters Kluwer Health)
Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Source:
Wiley
Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Source:
American Association for Cancer Research (AACR)
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Source:
Springer Science and Business Media LLC
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Source:
eScholarship, University of California
Linking provided by
